Lexicon Pharmaceuticals (LXRX) Payables (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Payables data on file, last reported at $3.0 million in Q1 2026.

• On a quarterly basis, Payables fell 71.97% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $3.0 million, a 71.97% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, down 79.17% from the prior year.
• Payables for Q1 2026 stood at $3.0 million, down from $3.1 million in the prior quarter.
• Over the last five years, Payables for LXRX reached as high as $14.8 million in Q4 2024 and fell as low as $3.0 million in Q1 2026.
• Historically, Payables has averaged $9.4 million across 5 years, with a median of $10.3 million in 2023.
• Across the five-year window, Payables surged 89.22% in 2022 and slumped 79.17% in 2025, its largest moves.
• Year by year, Payables stood at $10.4 million in 2022, then soared by 38.42% to $14.4 million in 2023, then advanced by 2.86% to $14.8 million in 2024, then slumped by 79.17% to $3.1 million in 2025, then dropped by 2.82% to $3.0 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $3.0 million in Q1 2026, $3.1 million in Q4 2025, and $3.8 million in Q3 2025.